Emerging evidence suggests a better option already exists. A recent meta-analysis by an international team of cardiologists ...

Early P2Y12 monotherapy after PCI for acute coronary syndrome was not noninferior compared with dual antiplatelet therapy ...

In high-risk patients, long-term aspirin added to oral anticoagulation worsened outcomes in the double-blind AQUATIC trial.

ASPREE’s first placebo trial in 2018 followed the participants for almost five years and at its conclusion warned of the risks of healthy older adults, those who had never had a heart attack or stroke ...

Aspirin, long the go-to for heart protection, may be dethroned. New research reveals clopidogrel, a blood thinner, reduces major cardiovascular events ...

Results presented at the Musculoskeletal Infection Society Annual Meeting showed use of aspirin was associated with decreased ...

Aspire’s sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes ...

Aspirin should not be Americans’ go-to pill to prevent cardiovascular disease, according to new proposed recommendations by the U.S. Preventive Services Task Force (USPSTF), an independent group that ...

Research from a Monash University-led team has confirmed 2018 research that found healthy older adults who took a low-dose of aspirin daily ...

Nature has long been the source of lifesaving medicines, from willow bark’s natural aspirin to new discoveries in tropical fruits. Now, chemists at the University of Delaware have pioneered a way to ...